 EBNA1 566-574, LQTHIFAEV.jpg)
EBV EBNA1 566-574, LQTHIFAEV
Description
About EBV EBNA1 566-574, LQTHIFAEV
The Epstein-Barr Virus (EBV) (strain B95-8) Epstein-Barr nuclear antigen (EBNA) 1 Peptide (IEDB: 101878) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Epstein-Barr nuclear antigen (EBNA) Peptide, H-LQTHIFAEV-OH (Uniprot: P03211 aa: 566-574) from JPT is produced under strict quality control and quality management.
EBV EBNA1 566-574, LQTHIFAEV - Specifications
- Peptide sequence: H-LQTHIFAEV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for EBV EBNA1 566-574, LQTHIFAEV
References:
Read References with JPT’s Antigen Peptides
EBV (strain B95-8) EBNA1 566-574, LQTHIFAEV has been described in:
Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma., Proc Natl Acad Sci U S A, 2009 (PMID: 19211798)
Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope., Immunology, 2010 (PMID: 19922423)
SARS-CoV-2-specific CD8<sup>+</sup> T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph., Immunol Cell Biol, 2021 (PMID: 34086357)
Documentation
Documentation for EBV EBNA1 566-574, LQTHIFAEV
Properties
Properties of EBV EBNA1 566-574, LQTHIFAEV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Epstein-Barr Virus (EBV) |
Protein Name: | Epstein-Barr nuclear antigen (EBNA) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to EBV EBNA1 566-574, LQTHIFAEV
Information | Values |
---|---|
Sequence: | H-LQTHIFAEV-OH |
Specifications: | 9mer peptide as TFA salt |